Physician profile
Wanda J Williams
NPI 1932158383
$3,069.65
in general payments reported to CMS, 2019-2025
21 companies · $438 in 2025
The $438 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $401 · 2021: $530 · 2022: $247 · 2023: $540 · 2024: $236 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,215.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $825.77 | 2019-2025 | |
| Tris Pharma INC | $757.35 | 2019-2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $205.33 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Cranial Technologies, INC | $179.90 | 2019-2024 | Doc Band |
| Organon LLC | $162.02 | 2025 | Vtama, Nexplanon |
| Glaxosmithkline, LLC. | $155.33 | 2019-2025 | Bexsero, Penmenvy, Pediarix |
| Sanofi Pasteur INC. | $128.72 | 2019-2025 | |
| Kaleo, INC. | $126.08 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.88 | 2020-2021 | |
| Aytu Biopharma, INC. | $66.05 | 2020-2021 | |
| Adlon Therapeutics L.P. | $60.83 | 2021 | |
| Seqirus USA INC | $59.62 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Neos Therapeutics, LP | $57.51 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $53.47 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $37.84 | 2019-2023 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $21.74 | 2025 | Fetroja |
| Emmaus Medical, INC. | $19.99 | 2021 | |
| Mylan Pharmaceuticals INC. | $19.69 | 2019 | |
| Alk-Abello, INC | $19.45 | 2025 | Neffy |
| Incyte Corporation | $15.48 | 2021 | |
| Noven Therapeutics, LLC | $13.60 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.